Intech Investment Management LLC Purchases 9,139 Shares of Glaukos Co. (NYSE:GKOS)

Intech Investment Management LLC grew its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 44.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,601 shares of the medical instruments supplier's stock after acquiring an additional 9,139 shares during the period. Intech Investment Management LLC owned about 0.05% of Glaukos worth $4,438,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of GKOS. BNP Paribas Financial Markets raised its position in Glaukos by 186.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier's stock valued at $1,788,000 after purchasing an additional 8,942 shares during the last quarter. First Turn Management LLC bought a new position in Glaukos in the 3rd quarter worth $12,520,000. Harbor Capital Advisors Inc. bought a new position in Glaukos in the 4th quarter worth $3,679,000. Victory Capital Management Inc. raised its holdings in Glaukos by 421.8% in the 3rd quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier's stock worth $10,320,000 after purchasing an additional 64,031 shares in the last quarter. Finally, State Street Corp raised its stake in Glaukos by 5.3% in the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock worth $254,626,000 after buying an additional 98,109 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Insider Transactions at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.40% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GKOS. Morgan Stanley lowered Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price objective for the company. in a research report on Monday, December 2nd. Stephens raised Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. Truist Financial lifted their target price on shares of Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Citigroup raised Glaukos from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Finally, Wells Fargo & Company boosted their price target on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $163.25.

Glaukos Price Performance

Shares of GKOS traded up $1.39 during mid-day trading on Friday, reaching $102.02. The stock had a trading volume of 1,040,792 shares, compared to its average volume of 585,823. The firm has a market cap of $5.77 billion, a price-to-earnings ratio of -35.55 and a beta of 0.99. Glaukos Co. has a 12 month low of $87.59 and a 12 month high of $163.71. The business has a fifty day moving average of $135.32 and a 200 day moving average of $136.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.